Cataract Clinical Trial
Official title:
Retrospective, Non-interventional, Comparative Clinical Investigation of the Safety and Performance of 690AD and 690ADY Monofocal Intraocular Lens Implantation
Verified date | May 2023 |
Source | Medicontur Medical Engineering Ltd |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Medicontur hydrophilic posterior chamber monofocal intraocular lens (IOLs) are indicated to improve vision at far distance in adults with cataract and/or ametropia (hyperopia, myopia), secondarily to removal of the crystalline lens. The intraocular lens is intended to be surgically implanted into the eye with the purpose of restoring optical function in the aphakic eye to provide an optical system with high predictability of the precalculated dioptric power. The study will be performed partially as a retrospective study with patients enrolled who had been implanted with 690AD or 690ADY IOLs mono- or binocularly between September 2021 - March 2022. Data from five visits will be collected: - Baseline preoperative (maximum 90 days prior to surgery)- retrospective - IOL implantation Day 0 - retrospective - Postoperative visit at Day 1 (+/- 0 days) - retrospective - Postoperative visit at 1 month (+/- 2 weeks) - retrospective - Postoperative visit at 12 months (+/- 3 months) - consent and prospective visit
Status | Completed |
Enrollment | 52 |
Est. completion date | June 7, 2023 |
Est. primary completion date | June 7, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Adult males or females above 18 years of age; - Pseudophakic patients implanted with 690AD or 690ADY monofocal IOLs (implanted between September 2021 - March 2022); - Diagnosis of cataract and/or ametropia (hyperopia, myopia); - Subject who has signed an informed consent form. - Patients who have participated in all visits that are subject to retrospective data collection. Exclusion Criteria: - - Patients who are not targeted to emmetropia. - Patients with the following condition(s) at the time of the baseline visit: - Corneal astigmatism > 1.0 diopter - Uncontrolled diabetic retinopathy - Iris neovascularization - Congenital eye abnormality - Uncontrolled glaucoma - Pseudoexfoliation syndrome - Amblyopia - Uveitis - AMD (advanced AMD) - Retinal detachment - Prior ocular surgery in personal medical history - Previous laser treatment - Corneal diseases - Severe retinal diseases (dystrophy, degeneration) - High myopia - Inadequate visualization of the fundus on preoperative examination - Patients deemed by the clinical investigator because of any systemic disease - Pregnancy - Eye trauma in medical history - Current use of systemic steroids or topical ocular medication - Patients with any eye condition that could affect vision in the opinion of the investigator at the time of the 12-month follow-up: (corneal ectasia, retinal diseases, glaucoma, uveitis, dry eye or amblyopia, etc.); |
Country | Name | City | State |
---|---|---|---|
Hungary | Szabolcs-Szatmár-Bereg Megyei Kórházak és Egyetemi Oktatókórház, Jósa András Oktatókórház | Nyíregyháza | |
Hungary | Pécsi Tudományegyetem, Klinikai Központ Szemészeti Klinika | Pécs |
Lead Sponsor | Collaborator |
---|---|
Medicontur Medical Engineering Ltd |
Hungary,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Intraoperative complications of cataract surgery | To verify that the frequency of the following complications does not exceed those stated in Acceptance criteria. | at Day1 postoperatively | |
Other | Postoperative complications of cataract surgery | To verify that the frequency of the following complications does not exceed those stated in Acceptance criteria. | at Month1 postoperatively | |
Other | Complications of IOL implantation | To verify that the frequency of the following complications does not exceed those stated in Acceptance criteria. | at Month12 postoperatively | |
Primary | CDVA | Monocular corrected distance visual acuity (CDVA) To compare monocular corrected distance visual acuity (CDVA) between groups implanted with 690AD and 690ADY monofocal IOLs at 12 months postoperatively. | 12 months postoperatively | |
Secondary | UDVA | Monocular uncorrected distance visual acuity (UDVA) To compare monocular uncorrected distance visual acuity (UDVA) between groups implanted with 690AD and 690ADY monofocal IOLs 12 months postoperatively. | 12 months postoperatively | |
Secondary | UDVA and CDVA | To compare percentage of eyes that achieve monocular UDVA and monocular CDVA within logMAR 0.0 or 0.3 between groups implanted with 690AD and 690ADY monofocal IOLs at 12 months postoperatively. | 12 months postoperatively | |
Secondary | Spherical Equivalent | Spherical Equivalent shall be used to calculate manifest residual refraction. To compare sphere, cylinder and axis of the eye between groups implanted with 690AD and 690ADY monofocal IOLs 12 months after IOL implantation. | 12 months postoperatively | |
Secondary | Patient satisfaction | Subjective perception of colour perception and scotopic vision shall be assessed by interviewing the patient using visual function questionnaire (VFQ-25 questionnaire) . To compare overall satisfaction, subjective perception of colour perception and scotopic vision between groups implanted with 690AD and 690ADY, postoperatively at 12 months. | 12 months postoperatively | |
Secondary | Cylinder | Cylinder shall be used to calculate manifest residual refraction. | 12 months postoperatively | |
Secondary | Axis of the eye | Axis of the eye shall be used to calculate manifest residual refraction. | 12 months postoperatively |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04685538 -
Chloroprocaine 3% Gel Eye Drop as Topical Anestheticsin Phacoemulsification.
|
Phase 3 | |
Recruiting |
NCT06060041 -
IC-8 Apthera IOL New Enrollment Post Approval Study
|
||
Recruiting |
NCT05518539 -
Evaluation of Quality of Vision and Visual Outcomes With Bilateral Implantation of the Clareon PanOptix Intraocular Lens
|
||
Recruiting |
NCT05271942 -
Tilt and Tumble vs Divide and Conquer - a Unique Comparison of the Two Cataract Surgery Methods
|
N/A | |
Active, not recruiting |
NCT04778501 -
PMCF Study on Monofocal Toric IOL (PODEYE TORIC) in Asia
|
N/A | |
Completed |
NCT05062564 -
Efficacy of LipiFlow in Patients Affected by Meibomian Gland Dysfunction in Reducing Post-cataract Surgery Dry Eye
|
N/A | |
Completed |
NCT03751033 -
Influence of DisCoVisc Ophthalmic Viscosurgical Device (OVD) on Intraoperative Aberrometry Readings
|
N/A | |
Completed |
NCT02529488 -
Investigation of AcrySof® IQ PanOptix™ Presbyopia-Correcting Intraocular Lens (IOL) Model TFNT00
|
N/A | |
Completed |
NCT04539548 -
A Study Assessing the Safety and Efficacy of Dextenza® for the Treatment of Ocular Pain and Inflammation Following Surgery for Pediatric Cataract
|
Phase 3 | |
Completed |
NCT03740659 -
Evaluation Of Aqueous Humor Of Levofloxacin-Dexamethasone Eye Drops And Of Its Components In Patients Undergoing Cataract Surgery
|
Phase 2 | |
Completed |
NCT03494257 -
Effect of Fixed Brinzolamide-brimonidine Combination on Intraocular Pressure After Phacoemulsification
|
N/A | |
Completed |
NCT05119127 -
Rotational Stability of Acrysof IQ Vivity Extended Vision Toric IOL and Refractive Visual Outcome.
|
N/A | |
Active, not recruiting |
NCT04271709 -
Manhattan Vision Screening and Follow-Up Study (NYC-SIGHT)
|
N/A | |
Recruiting |
NCT03713268 -
Intraoperative OCT Guidance of Intraocular Surgery II
|
||
Completed |
NCT03739528 -
Levo-Dexa vs. Tobra+Dexa for Prevention and Treatment of Inflammation and Prevention of Infection in Cataract Surgery
|
Phase 3 | |
Completed |
NCT02888210 -
A Study Assessing Safety and Efficacy of MD-15 Intraocular Lens in Patients With Aphakic Eye After Cataract Surgery
|
Phase 3 | |
Completed |
NCT03356847 -
Evaluation of the Rotational Stability of the Monofocal SISA Implant Following Cataract Surgery
|
N/A | |
Completed |
NCT04332640 -
Clinical Evaluation of the Next Generation Phaco System
|
N/A | |
Recruiting |
NCT03638726 -
Subconjunctival Atropine and Intracameral Epinephrine for Pupil Dilation in Phacoemulsification
|
Phase 4 | |
Completed |
NCT03050697 -
Evaluation of the Safety and Performance of the HARMONI® Toric Lens
|
N/A |